Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

NCT05156320 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Spinal Muscular Atrophy
Spinal Muscular Atrophy Type 3
Spinal Muscular Atrophy Type 2
SMA
Neuromuscular Diseases
Muscular Atrophy
Atrophy
Muscular Atrophy, Spinal
Neuromuscular Manifestations
Anti-myostatin

Interventions

DRUG: Apitegromab
DRUG: Placebo

Sponsor

Scholar Rock, Inc.